Researchers use magnets to direct cancer drugs; Oral delivery tech could boost HIV therapy;

 @DamianFierce: Aptar Pharma has bought a French company for $207M to expand its injectable delivery offerings. Story | Follow @DamianFierce

> Researchers in Scotland and Australia have developed an iron-based nanocasing for the cancer drug Cisplatin, using small external magnets to direct the drug to its target. News

> University of British Columbia scientists have received funding from the National Research Council of Canada to investigate whether their novel oral delivery method can be paired with existing HIV treatments to boost effectiveness. Report

> Roymer Biomedical has received the FDA's OK to begin human trials of AppliGel-G, a polymer-based drug delivery platform for ulcer treatment. Story

> Using silica nanosheets, researchers in Australia have developed flake-coated nanocapsules that allow for controlled-release delivery. Article

> Israeli drug delivery company D. Medical reported a $1.2 million loss in the first quarter, and the company plans to seek outside investment until it can subsist on its revenue. Release

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.